PBYI - Puma Biotechnology, Inc.
| Previous Close | 13.86 |
| Open | 13.81 |
| Bid | 0.00 x 900 |
| Ask | 14.67 x 800 |
| Day's Range | 13.39 - 14.20 |
| 52 Week Range | 12.81 - 65.45 |
| Volume | 5,620,065 |
| Avg. Volume | 1,095,047 |
| Market Cap | 533.237M |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.13 |
- Markit•6 days ago
See what the IHS Markit Score report has to say about Puma Biotechnology Inc.
Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for PBYI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $2.55 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•10 days ago
Did You Manage To Avoid Puma Biotechnology's (NASDAQ:PBYI) Devastating 77% Share Price Drop?
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- Zacks•16 days ago
Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•19 days ago
Here's Why Puma Biotechnology Tumbled 53.9% in May
The most significant potential concern for the company's lone drug product arose.
- Business Wire•19 days ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on June 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 82,063 shares of Puma common stock to 15 new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire•20 days ago
Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. “Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial,” was presented as an oral presentation by Adam M. Brufsky, MD, PhD, Professor of Medicine, Co-Director, Comprehensive Breast Cancer Center, Magee Women’s Hospital of the University of Pittsburgh Medical Center.
- Business Wire•20 days ago
CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
In the release dated June 2, 2019, please replace the PDF file with the accompanying corrected file.
- Business Wire•22 days ago
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. , a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.
- Business Wire•26 days ago
Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
- Motley Fool•last month
Investors Are Right to Worry About Puma Biotechnology
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
Market Realist•last monthHow Are Expenses Trending for Puma Biotechnology in 2019?
Is Puma Biotechnology an Attractive Pick after Q1 Results?(Continued from Prior Part)Expenses in the first quarterIn the first quarter, Puma Biotechnology (PBYI) reported SG&A (selling, general, and administrative) expenses of $45.50 million, a
Market Realist•last monthAnalysts Expect Puma Biotechnology to Become Profitable in 2020
Is Puma Biotechnology an Attractive Pick after Q1 Results?(Continued from Prior Part)Cash burnIn its first-quarter earnings conference call, Puma Biotechnology (PBYI) highlighted its cash burn of $15 million in the first quarter, which compares
Market Realist•last monthPuma Biotechnology Reduced Guidance for NERLYNX Sales
Is Puma Biotechnology an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn its first-quarter earnings conference call, Puma Biotechnology (PBYI) reduced its guidance for fiscal 2019 net sales of NERLYNX in the US market
- Market Realist•last month
What Analysts Are Recommending for Puma Biotechnology
Is Puma Biotechnology an Attractive Pick after Q1 Results?Share price movementsOn May 10, Puma Biotechnology (PBYI) reported first-quarter results. The company reported revenues of $99.1 million, a YoY rise of 49.02%. According to the first-quarter
- Benzinga•last month
Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would hold off for now from Village Farms International Inc (NASDAQ: VFF ). He is not a buyer of Sailpoint Technologies Holdings Inc ...
- Investor's Business Daily•last month
Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug
Puma stock was hammered Friday after sales of breast cancer treatment Nerlynx lagged the Street by north of $20 million despite a first-quarter price hike. Puma also cut its 2019 outlook.
- Motley Fool•last month
Here's Why Puma Biotechnology Fell as Much as 40.7% Today
There are risks to having only one marketed drug product.
- TheStreet.com•last month
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales
plunged on Friday after the company revealed that more patients than expected were discontinuing treatment with its breast cancer drug, Nerlynx, spurring a sharp drop in sales and prompting several analysts to downgrade the company's stock. Puma shares slumped more than 38% in trading on the Nasdaq Stock market, plunging $11.52 to $18.50 after the company said in its first-quarter earnings release that large numbers of patients are discontinuing their use of the company's only drug - Nerlynx - because of adverse side effects of severe diarrhea. , was approved by the Food and Drug Administration in July 2017 to prevent breast cancer relapse following therapy in patients with HER2-positive cancer.
- Benzinga•last month
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Shares of small-cap oncology biotech Puma Biotechnology Inc (NASDAQ: PBYI ) are sinking to their lowest level since November following the release of its first-quarter results. Nerlynx Numbers Disappoint ...
- Zacks•last month
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
